News | December 21, 2024
Lonza expands capsule manufacturing capacity in India and China
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
This approval reflects company’s unwavering commitment that the quality assurance
Subscribe To Our Newsletter & Stay Updated
